三友医疗(688085.SH)发布股东询价转让计划书，拟参与本次询价转让股东为QM5LIMITED，拟转让股 份的总数为666.925万股，占公司总股本的比例为2%。 ...

人民财讯9月22日电，三友医疗(688085)9月22日公告，公司持股14.74%的股东QM5 LIMITED拟询价转 让公司股份约666.93万股，占公司总股本的2%。受让方通过询价转让受让的股份，在受让后6个月内不 得转让。 转自：证券时报 ...

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1] Core Viewpoints - The growth of healthcare expenses, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating that commercial health insurance may provide a solution to the pressures faced by the medical insurance system [3][15] - The commercial health insurance sector is expected to grow significantly, with premiums projected to reach 97.74 billion yuan by 2024, driven by low penetration rates and the need for additional funding sources [20][24] - Policies are increasingly supportive of commercial health insurance, particularly in relation to innovative drugs, which are now being included in the commercial health insurance directory [71][76] Summary by Sections Part 1: Healthcare Financing System - The healthcare financing system in China consists of government, social, and personal contributions, with social contributions being the main driver for future growth [10][15] Part 2: Growth of Health Insurance - The commercial health insurance market is expected to fill a significant funding gap, with an estimated shortfall of over 1.7 trillion yuan by 2030 [21][22] - Medical insurance is the primary source of compensation within commercial health insurance, with a compensation rate of approximately 68.79% in 2022 [27][31] Part 3: Core Products of Medical Insurance - The report highlights the importance of medical insurance as a key focus area, noting that it directly compensates for medical expenses, unlike critical illness insurance [31][35] Part 4: Policy Support for Health Insurance Development - A series of policies since 2009 have aimed to promote the development of commercial health insurance, with specific targets for market size and coverage [71][72] Part 5: Investment Recommendations - The report suggests focusing on innovative drug companies with rich pipelines, DTP pharmacies, and companies in the TPA industry, as well as innovative medical devices and high-end medical service providers [77]

证券代码：688085 证券简称：三友医疗 公告编号：2025-073 上海三友医疗器械股份有限公司 股东询价转让计划书 QM5 LIMITED（以下简称"出让方"）保证向上海三友医疗器械股份有限公 司（以下简称"公司"或"三友医疗"）提供的信息内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托中信证券股份有限公司（以下简称"中信证券"）组织实施本次询 价转让。截至 2025 年 9 月 22 日，出让方所持首发前股份的数量、占总股本比例 情况如下： | 序号 | 股东名称 | 持股数量（股） | 持股占总股本比例 | | --- | --- | --- | --- | | 1 | QM5 LIMITED | 49,146,564 | 14.74% | 出让方声明，出让方所持股份已经解除限售，权属清晰。出让方不存在《上 市公司股东减持股份管理暂行办法》、《上海证券交易所上市公司自律监管指引 第 15 号— ...

中信证券股份有限公司 关于上海三友医疗器械股份有限公司股东 向特定机构投资者询价转让股份 相关资格的核查意见 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 1 | 企业名称 | QM5 | LIMITED | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 类型 | 外资企业 | | 成立日期 | | 2013 年 | 10 | 月 29 | 日 | | 注册地址 | | 香港皇后大道中 15 | 号置地广场告罗士打大厦 | 42 楼 | 4205-06 | 室 | | | | 主营业务 | 对外投资 | | | | | | | | 中信证券股份有限公司（以下简称"中信证券"）受上海三友医疗器械股份 有限公司（以下简称"三友医疗"）股东 QM5 LIMITED（以下简称"出让方"） 委托，组织实施本次三友医疗首发前股东向特定机构投资者询价转让（以下简称 "本次询价转让"）。 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》《科创 板上市公司持续监管办法（试行）》《上海证券交易所科创板股票上市规 ...

证券代码：688085 证券简称：三友医疗 公告编号：2025-072 上海三友医疗器械股份有限公司 关于联营公司产品通过创新医疗器械特别审查程序 的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海三友医疗器械股份有限公司（以下简称"公司"）孵化并投资的联营公 司春风化雨（苏州）智能医疗科技有限公司（以下简称"春风化雨"）脊柱手术 机器人及其相关智能化产品于近日通过国家药品监督管理局医疗器械技术审评 中心创新医疗器械特别审查程序，并被命名为脊柱外科手术导航定位系统，现将 相关情况公告如下： 一、产品基本信息 申报产品名称：脊柱外科手术导航定位系统 申请人：春风化雨（苏州）智能医疗科技有限公司 产品管理类别：第三类 二、产品情况介绍 本次通过国家药品监督管理局医疗器械技术审评中心创新医疗器械特别审 查程序的产品为春风化雨自行研发制造的手术机器人，具有首创的多臂手术机器 人技术。产品的主要创新优势如下： 1、创新性地将传统的单臂手术机器人升级为三臂手术机器人。其中，头部 视觉臂专注于手术过程中的精准定位与实时 ...

格隆汇9月22日丨三友医疗(688085.SH)公布，拟参与三友医疗首发前股东询价转让（以下简称"本次询 价转让"）股东为QM5 LIMITED；出让方拟转让股份的总数为6,669,250股，占三友医疗总股本的比例为 2.00%；本次询价转让为非公开转让，不会通过集中竞价交易或大宗交易方式进行。受让方通过询价转 让受让的股份，在受让后6个月内不得转让。 ...

智通财经APP讯，三友医疗(688085.SH)发布股东询价转让计划书，拟参与本次询价转让股东为QM5 LIMITED，拟转让股份的总数为666.925万股，占公司总股本的比例为2%。 ...

Core Viewpoint - The approval of the spinal surgery robot and related intelligent products by the National Medical Products Administration marks a significant milestone for the company and its innovation strategy in the medical device sector [1][2]. Group 1: Product Development - The spinal surgery robot, named the spinal surgical navigation positioning system, integrates advanced technologies such as multi-arm robotic systems, lightweight medical-grade mechanical structures, electromagnetic navigation, and optical imaging [1]. - The new generation of surgical robots aims to enhance AI intelligence, enabling clinical doctors to perform surgeries more accurately and safely, with customizable solutions based on specific surgical needs [1]. Group 2: Market Impact - The approval of the product for the innovative channel is a key milestone in the company's innovation research and development system, contributing to its growth strategy [2]. - The company’s other subsidiary, Suzhou Yunhejing, has also developed a "surface porous polyether ether ketone interbody fusion device," which is expected to enter the innovative channel by April 2025, further enhancing the company's product offerings [2].

Core Viewpoint - Sanyou Medical (688085.SH) announced that its incubated and invested joint venture, Chuanfeng Huayu (Suzhou) Intelligent Medical Technology Co., Ltd., has received approval for its spinal surgery robot and related intelligent products through the National Medical Products Administration's special review procedure for innovative medical devices, marking a significant milestone in the company's innovation and R&D system for 2025 [1] Group 1 - The product has been named the Spinal Surgery Navigation and Positioning System, indicating its advanced technological capabilities [1] - This approval allows the product to enter an innovative channel, which will provide priority processing rights during the registration application, effectively shortening the product registration cycle and accelerating its market launch [1] - The successful market approval of this product will positively impact the promotion and usage of related products under the innovative channel, enhancing the company's business prospects [1] Group 2 - Previously, another subsidiary of the company, Suzhou Yunhejing New Material Technology Co., Ltd., developed a "Surface Porous Polyether Ether Ketone Interbody Fusion Device," which also entered the innovative channel in April 2025 [1] - The entry of both products into the innovative medical device special review procedure signifies the company's commitment to advancing its product offerings in the medical technology sector [1]